Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of 14,090,000 shares of common stock at a public offering price of $35.50 per share under its Form S-3 shelf registration. Underwriters have a 30-day option to purchase up to 2,113,500 additional shares at the public offering price less underwriting discounts and commissions.
Gross proceeds are expected to be $500.2 million (or $575.2 million if the option is exercised in full), with net proceeds to Amylyx of approximately $471.7 million (or $542.5 million with full option exercise) after underwriting discounts, commissions and estimated expenses. As of June 30, 2026, 111,368,283 shares of common stock were outstanding.
Amylyx plans to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund the potential U.S. commercial launch of its lead investigational drug avexitide for post-bariatric hypoglycemia if approved, including securing commercial manufacturing capacity, and for research and development, working capital and other general corporate purposes. The company disclosed that the offering will cause immediate dilution of $29.83 per share to new investors based on the offering price.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of up to $350,000,000 of its common stock under an effective shelf registration. The shares trade on Nasdaq Global Select Market under the symbol AMLX, with a closing price of $35.11 on August 18, 2026.
Amylyx is a pre-commercial pharmaceutical company focused on endocrine and neurodegenerative diseases. Its lead asset, avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism, has U.S. FDA Breakthrough Therapy, Rare Pediatric Disease and Orphan Drug Designations. The Phase 3 LUCIDITY trial in PBH met its FDA-agreed primary endpoint, showing a 55% reduction in Level 2 and 3 hypoglycemic events versus placebo (p=0.000003), with a generally favorable safety profile.
The company plans to submit a New Drug Application for avexitide by the end of 2026 and is arranging commercial supply through contract manufacturers. Other programs include AMX0035 in Wolfram syndrome, AMX0114 in ALS, and long-acting GLP-1 antagonist AMX0318. Net proceeds will be used with existing cash to fund a potential U.S. avexitide launch, expand manufacturing capacity, and support R&D, working capital and general corporate purposes, while existing shareholders will experience dilution from this equity issuance.
Amylyx Pharmaceuticals, Inc. reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass. The randomized, double-blind, placebo-controlled study in 78 participants met its FDA-agreed primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (rate ratio 0.45, 95% CI 0.32–0.63, p=0.000003), and met all secondary endpoints. Avexitide was generally well-tolerated, with no treatment-related serious adverse events and mostly mild or moderate side effects. PBH currently has no approved therapies and affects an estimated ~160,000 people in the U.S. Amylyx plans an NDA submission to the FDA by the end of 2026 and is preparing for a potential commercial launch of avexitide in 2027, supported by orphan drug designation, expected NCE exclusivity, and patent rights through 2037 with potential extensions.
Amylyx Pharmaceuticals reported positive topline Phase 3 LUCIDITY results for avexitide, an investigational first-in-class GLP‑1 receptor antagonist for post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass. The 78-participant, randomized, double-blind, placebo-controlled trial met the FDA-agreed primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo through Week 16 (p=0.000003).
LUCIDITY also met all secondary endpoints, with highly statistically significant and clinically meaningful reductions in Level 2 and Level 3 events by both self-monitoring of blood glucose and continuous glucose monitoring. Avexitide 90 mg once daily was generally well tolerated, with mostly mild to moderate adverse events and no serious adverse events related to treatment, and no body-weight changes over 16 weeks. Amylyx plans to submit a New Drug Application by the end of 2026 and is preparing for a potential U.S. commercial launch in 2027, if approved. Avexitide already holds FDA Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug designations across PBH and congenital hyperinsulinism.
Amylyx Pharmaceuticals reported Q2 2026 results showing continued investment in its rare-disease pipeline and a net loss driven by research and pre-commercial activities. Operating expenses for the quarter were $45,693 thousand, including research and development of $23,768 thousand and selling, general and administrative costs of $21,925 thousand.
The company ended June 30, 2026 with $250.8 million in cash, cash equivalents and marketable securities and states this should fund operations into 2028. Its lead asset avexitide is in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with last-participant 16-week visits complete and topline data expected in the third quarter of 2026. Additional programs include AMX0035 in Wolfram syndrome, AMX0114 in ALS, and AMX0318 in IND-enabling studies. Amylyx also agreed in principle to settle a securities class action for $6.5 million, with a significant portion funded by insurance proceeds, while related derivative actions remain under negotiation.
Amylyx Pharmaceuticals reported a second quarter 2026 net loss of $43.4 million, or $0.39 per share, compared with a net loss of $41.4 million, or $0.46 per share, a year earlier. Research and development expenses were $23.8 million, down from $27.2 million, while selling, general and administrative expenses rose to $21.9 million from $15.6 million, driven mainly by higher legal costs and commercial initiatives.
Cash, cash equivalents and short-term investments totaled $250.8 million as of June 30, 2026, versus $279.8 million at March 31, 2026, and the company expects its current cash runway to fund operations into 2028.
Operationally, the last participant has completed the final study visit in the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with topline data anticipated in late August or early September 2026 and a potential U.S. commercial launch in 2027 if approved. Amylyx also advanced an expanded access program for avexitide, continued development of AMX0114 for ALS, progressed AMX0318 toward an IND targeted for 2027, and reported longer-term data for AMX0035 in Wolfram syndrome.
Amylyx Pharmaceuticals, Inc. insider Gina Mazzariello, Chief Legal Officer, reported two open-market sales of common stock. On July 9, 2026, she sold 15,000 shares at a weighted average price of $18.3164 per share, and on July 10, 2026 she sold another 15,000 shares at a weighted average price of $17.6081 per share. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. Following the transactions, she holds 179,090 shares of Amylyx Pharmaceuticals common stock directly.
Amylyx Pharmaceuticals director Bernhardt G. Zeiher received a grant of 24,372 stock options. These options give the right to buy 24,372 shares of Amylyx common stock at an exercise price of $14.31 per share and expire on June 3, 2036.
According to the terms, the options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as the director remains in continuous service with the company through that vesting date. After this grant, the director holds 24,372 derivative securities directly.
Amylyx Pharmaceuticals director Karen Firestone received a grant of stock options covering 24,372 shares of common stock at an exercise price of $14.31 per share. These options vest in full on the earlier of June 4, 2027 or the next annual meeting, provided she remains in continuous service, and bring her directly held option position reported in this filing to 24,372 shares.